CHSYF (China Medical System Holdings) Beneish M-Score: -1.96 (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHSYF China Medical System Holdings Ltd CHSYF
87 GF Score
Price $1.57
GF Value $1.30
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is China Medical System Holdings Beneish M-Score?

China Medical System Holdings CHSYF +0.11% 87 Beneish M-Score is -1.96 as of Jul. 31, 2026. GuruFocus rates CHSYF with a GF Score™ of 87/100 and a GF Value™ of $1.30 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 912 Drug Manufacturers companies, China Medical System Holdings ranks worse than 80.26% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.96 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for China Medical System Holdings's Beneish M-Score or its related term are showing as below:

CHSYF' s Beneish M-Score Range Over the Past 10 Years
Min: -2.84   Med: -2.36   Max: -1.96
Current: -1.96

During the past 13 years, the highest Beneish M-Score of China Medical System Holdings was -1.96. The lowest was -2.84. And the median was -2.36.


China Medical System Holdings Beneish M-Score Historical Data

* Premium members only.

The historical data trend for China Medical System Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Medical System Holdings Beneish M-Score Chart

China Medical System Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.25 -2.70 -2.59 -2.32 -1.96

China Medical System Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.59 0.00 -2.32 0.00 -1.96

CHSYF vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Medical System Holdings Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where China Medical System Holdings's Beneish M-Score falls into.


CHSYF
87GF Score
China Medical System Holdings Ltd CHSYF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Medical System Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of China Medical System Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.196+0.528 * 1.0153+0.404 * 0.9992+0.892 * 1.1366+0.115 * 0.979
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9799+4.679 * 0.038048-0.327 * 0.9169
=-1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was $347 Mil.
Revenue was $1,166 Mil.
Gross Profit was $834 Mil.
Total Current Assets was $1,320 Mil.
Total Assets was $2,726 Mil.
Property, Plant and Equipment(Net PPE) was $63 Mil.
Depreciation, Depletion and Amortization(DDA) was $38 Mil.
Selling, General, & Admin. Expense(SGA) was $526 Mil.
Total Current Liabilities was $209 Mil.
Long-Term Debt & Capital Lease Obligation was $3 Mil.
Net Income was $211 Mil.
Gross Profit was $0 Mil.
Cash Flow from Operations was $108 Mil.
Total Receivables was $255 Mil.
Revenue was $1,026 Mil.
Gross Profit was $745 Mil.
Total Current Assets was $1,196 Mil.
Total Assets was $2,479 Mil.
Property, Plant and Equipment(Net PPE) was $62 Mil.
Depreciation, Depletion and Amortization(DDA) was $36 Mil.
Selling, General, & Admin. Expense(SGA) was $473 Mil.
Total Current Liabilities was $208 Mil.
Long-Term Debt & Capital Lease Obligation was $2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(347.262 / 1165.956) / (255.464 / 1025.862)
=0.297835 / 0.249024
=1.196

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(744.735 / 1025.862) / (833.646 / 1165.956)
=0.72596 / 0.714989
=1.0153

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1320.219 + 63.336) / 2725.871) / (1 - (1195.608 + 61.545) / 2478.854)
=0.492436 / 0.492849
=0.9992

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1165.956 / 1025.862
=1.1366

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(35.606 / (35.606 + 61.545)) / (37.899 / (37.899 + 63.336))
=0.366502 / 0.374367
=0.979

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(526.469 / 1165.956) / (472.721 / 1025.862)
=0.451534 / 0.460804
=0.9799

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.076 + 208.602) / 2725.871) / ((1.718 + 208.23) / 2478.854)
=0.077655 / 0.084696
=0.9169

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(211.394 - 0 - 107.681) / 2725.871
=0.038048

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

China Medical System Holdings has a M-score of -1.96 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.96 mean?
China Medical System Holdings (CHSYF) has a Beneish M-Score of -1.96 as of Jul. 31, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on China Medical System Holdings and its competitors. According to the industry distribution chart, China Medical System Holdings ranks #732 out of 912 companies in the Drug Manufacturers industry, placing it in the top 80.3%.
Is China Medical System Holdings' Beneish M-Score too high?
China Medical System Holdings' current Beneish M-Score is -1.96. Based on the distribution chart, China Medical System Holdings ranks #732 out of 912 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, China Medical System Holdings has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Medical System Holdings ranks #732 out of 912 companies for Beneish M-Score. This places China Medical System Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on China Medical System Holdings and its competitors. China Medical System Holdings's current Beneish M-Score is -1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (CHSYF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.30, compared to a current price of $1.57 — trading 20.8% above its estimated fair value. The current Beneish M-Score is -1.96. China Medical System Holdings' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For China Medical System Holdings (CHSYF), the current Beneish M-Score is -1.96 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Medical System Holdings (CHSYF) Overvalued in 2026?

Based on GuruFocus' analysis, China Medical System Holdings stock appears to be overvalued. The current stock price of $1.57 is trading 20.8% above its estimated GF Value™ of $1.30. GuruFocus considers China Medical System Holdings to be Modestly Overvalued.

Key valuation signals for CHSYF:

  • Beneish M-Score: -1.96
  • GF Value™: $1.30 vs. price of $1.57 (20.8% above fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the CHSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Medical System Holdings Business Description

Address 510 King’s Road, Unit 2106, 21st Floor, Island Place Tower, North Point, Hong Kong, HKG
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
87GF Score

Get the complete analysis for CHSYF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.57
Price
$1.30
GF Value